The gene editing industry has faced numerous challenges in recent years, with layoffs, closures, and sinking stock prices casting a shadow over its future. However, a ray of hope emerged earlier this month in the form of KJ Muldoon, a 6-month-old baby who received a custom gene editing treatment to correct his unique mutation.
While KJ is not cured, the treatment has allowed him to resume a normal diet and has prevented him from needing a liver transplant. This breakthrough was shared at the annual American Society of Gene & Cell Therapy meeting in New Orleans, renewing optimism within the industry. Nessan Bermingham, co-founder of Intellia, one of the pioneering CRISPR companies, expressed excitement about the progress made in gene editing.
The news of KJ’s successful treatment couldn’t have come at a better time for a field that has been struggling to find its footing. For three years, gene editing has faced setbacks and uncertainties, making KJ’s story a much-needed reminder of the potential of this technology. The impact of gene editing on KJ’s life serves as a testament to the advancements made in the past decade.
Despite the positive outcome for KJ, access to the full article detailing his treatment and its implications is restricted to STAT+ subscribers. The exclusive content offers in-depth coverage and analysis of the biotech sector, providing valuable insights for industry professionals and enthusiasts. By subscribing to STAT+, readers can unlock the full story of KJ Muldoon and stay informed about the latest developments in gene editing and beyond.
To read the complete article and explore subscription plans, interested readers can visit the STAT+ website and choose from individual or group plans. Subscribing to STAT+ will grant access to a wealth of premium content, including exclusive stories, daily coverage, and expert analysis in the biotech field. Don’t miss out on the opportunity to delve deeper into KJ’s story and the future of gene editing by becoming a STAT+ subscriber today.
